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Abstract 
Review on TACC2, with data on DNA/RNA, on 
the protein encoded and where the gene is 
implicated. 
Identity 
Other names: AZU-1, ECTACC 
HGNC (Hugo): TACC2 
Location: 10q26.13 
Note 
Based on published GenBank sequences, this gene 
has seven potential transcription start sites located 
at 123748689 bp, 123754142 bp, 123872554 bp, 
123886229 bp, 123922941 bp, 123951963 bp, 
123969557 bp from pter. 
DNA/RNA 
Description 
The gene is composed of 28 exons spanning 
265369 bp. 
Transcription 
Transcripts depicted above encompass most 
transcripts evident in AceView and USGC genome 
browsers.  
Most other AceView "transcripts" appear to be 
subsets of those shown or unspliced. AF176646 
represents the published "Azu-1" variant (Chen et 
al., 2000); although no other cDNAs support the 5' 
end as a transcriptional start site (123886229 bp), a 
H3K27 acetylation cluster is noted in this region 
(ENCODE Project Consortium, 2011). 
 










AF220152 represents the "ECTACC variant" (Pu et 
al., 2001), first 13 bases of which do not match the 
genomic DNA and no other cDNAs support its 5' 
end as a transcriptional start site.  
Transcription start site at 123754142 bp identified 
in a global search for alternative promoters (Kimura 
et al., 2006) and supported by three cDNAs 
(AL833304, DB276457 and AK094848). 
AL8333304 does not encode a protein as it appears 
to use a "non canonical" splice site at 123781503, 4 
nucleotides after initiator codon for the TACC2 
"long isoforms". DB276457 appears to be 
incomplete at the 3' end due to the nature of its 
isolation (Kimura et al., 2006). 
Protein 
Description 
Ten isoforms are predicted based on published 
cDNA sequences. Features will be referenced to 
their location in the largest AAO62630 isoform 
(2948 amino acids, 309403,40 Da). The nine other 
isoforms are: AAI44600, 2875 amino acids, 
302586,86 Da; AAI44601, 2826 amino acids, 
296742,08 Da; AAO62629, 1094 amino acids, 
119330,60 Da; AAC64968, 1026 amino acids, 
112110,91 Da; AAH39311, 996 amino acids, 
108703,96 Da; BAH12132, 601 amino acids, 
64367,07 Da; AAF29537, 906 amino acids, 
99590,14 Da; ORF-BC015736 (longest open 
reading frame of GB:BC015736), 575 amino acids, 
64675,57 Da; AAF63433, 571 amino acids, 
64156,01 Da. 
ORF-BC015736 and AAF63433, beginning at an 
"internal" AUG present in exon 9, are identical 
except for 4 amino acids missing in AAF63433 
(amino acid 2429-2432). BAH12132 prematurely 
terminates due to a C-T mutation in the cDNA 
generating a nonsense codon; the partial cDNA 
coding this open reading frame is identical to other 
TACC2 isoforms downstream of the nonsense 
codon, suggesting the mutation is a cloning artefact. 
Western blot analysis confirms the large ≈ 300 kDa 
isoforms and those of ≈ 100 kDa. Western blot 
often shows species 65-70 kDa (corresponding in 
size to ORF-BC015736 and AAF63433 isoforms), 
however the variability in intensity in different 
preparations from the same cell type suggests that 
these species could also arise as a product of 
degradation (PEST sequences support that TACC2 
is subject to regulated degradation). 
PSORT II predicts multiple nuclear localisation 
signals between amino acid 2128 and 2420 
(http://psort.hgc.jp/form2.html). Multiple 
phosphorylation sites have been identified 
throughout the protein sequence by mass 
spectrometry (summarized at PhosphoSitePlus 
(Hornbeck et al., 2012)).  










The following lysine modifications are noted: 
lysine trimethylation at K1339 and K1346 (Cao et 
al., 2013); ubiquitylation at K2542 in HCT116 
colon cancer cells (Kim et al., 2011); acetylation at 
K2884 in A549 lung cancer cells (Choudhary et al., 
2009), K2736 in a resected liver cancer, K2927 and 
K2928 in NCI H2228 non small cell lung cancer 
cells (Hornbeck et al., 2012). 
Expression 
Short isoforms (100-120 kDa) widely expressed in 
fetal and adult tissue, but large isoforms (≈ 300 
kDa) expressed at high levels in muscle tissue 
(Lauffart et al., 2003). Short form(s) expression is 
upregulated by erythopoietin in human 
microvascular endothelial cells (Pu et al., 2001) and 
androgens in prostate cancer cells (Takayama et al., 
2012). Induction of large forms occurs as 
development proceeds in the tissues that express 
them (Still et al., unpublished). 
Localisation 
TACC2 short isoforms can be located in the 
nucleus and/or cytosol of interphase cells (Chen et 
al., 2000; Gergely et al., 2000; Lauffart et al., 
2003). TACC2 interacts with the centrosome and 
mitotic spindle during mitosis (Gergely et al., 
2000).  
In some cells, overexpression can result in 
accumulation of the protein into cytoplasmic 
punctate structures due to oligmerisation (Gergely 
et al., 2000). The oligomerisation motif is located 
between amino acid 2740 and 2815 (Tei et al., 
2009). 
Function 
TACC2 plays a role in microtubule dynamics 
during mitosis based upon interactions with Aurora 
C kinase (Tien et al., 2004) and CKAP5 (ch-
TOG/XMAP215) via the TACC domain (see Peset 
and Vernos, 2008 for Review). TACC2 is 
implicated in G2/M progression (Takayama et al., 
2012) and its ability to function in the maintenance 
of normal mitotic spindle dynamics is targeted by 
SV40 T-antigen (Tei et al., 2009).  
TACC2 is an effector of a mitotic checkpoint 
control kinase, TTK, with disruption of TTK 
activity preventing phosphorylation of 100-120 kD 
TACC2 short isoforms, subsequent recruitment of 
the TACC2 to the centrosome, leading to reduction 
of centrosome-centrosome distance in mitotic cells 
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(Dou et al., 2004). TACC2 also interacts with 
mitotic regulatory proteins Haus 1, Haus 4 and 
PRC1 (Hutchins et al., 2010). 
Alternative functions have been ascribed in 
transcription through direct interaction with 
coregulators FHL2 and FHL3 proteins (Lauffart et 
al., 2007b), YEATS4 (GAS41) and the SWI/SNF 
chromatin remodeling complex (Lauffart et al., 
2002), histone acetyltransferases KAT2A 
(hGCN5L2)/KAT2B (pCAF)/Ep300/CREBBP 
(Gangisetty et al., 2004), a core component of a 
histone deacetylase complex, HMG20B (BRAF35) 
(Stelzl et al., 2005) and the retinoid-X receptor 
(Vettaikkorumakankauv et al., 2008).  
TACC2 enhances transcriptional regulation from a 
cAMP response element (Lauffart et al., 2007b), 
and retinoid-X-receptor responsive genes 
(Vettaikkorumakankauv et al., 2008).  
Interaction with nucleoporin NUP155 has been 
identified by mass throughput technologies 
(Havugimana et al., 2012). 
TACC2 is found in complexes containing BRCA1, 
BARD1, p53 and Ku70 and may therefore also 
have a role in DNA damage/repair (Lauffart et al., 
2007a). 
TACC2 is phosphorylated during mitosis 
(Dephoure et al., 2008; Olsen et al., 2010) and in 
response to activation of EGFR and oncogenic 
signaling pathways (Rikova et al., 2007; Chen et 
al., 2009; Moritz et al., 2010).  
Tumour suppressive properties of TACC2 are 
thought to function through the PLCγ pathway 
(Cheng et al., 2011). PPP1CC, protein phosphatase 
1 may be involved in dephosphorylation of TACC2 
(Esteves et al., 2013).  
Acetylation, ubiquitylation and trimethylation of 
TACC2 may also impact TACC2's function 
(Choudhary et al., 2009; Kim et al., 2011; 
Hornbeck et al., 2012; Cao et al., 2013). 
Homology 
Member of the TACC family, based on the 
presence of the conserved approximately 200 amino 
acid carboxy terminal coiled coil domain (TACC 
domain) (Still et al., 1999; Still et al., 2004).  
Both TACC1 and TACC2 contain a 16 amino acid 
SFP motif SSDSE-X2- FETPE-X2-TP, and a 
conserved string of nine amino acids, 
HATDEEKLA.  
These two motifs are specific to TACC1 and 2 
only.  
Additionally, TACC2 contains two copies of the 33 
amino acid SDP repeat, which is conserved 
between the members of the vertebrate TACC 
family (Lauffart et al., 2002).  
In TACC1, the SDP repeat serves as the binding 
site for the SWI/SNF component/accessory factor, 
YEATS4 (Lauffart et al., 2002). 
Mutations 
Note 
To date, no mutations in the TACC2 gene have 
been detected. 
Implicated in 
Infant acute lymphoblastic leukemia 
Prognosis 
In a gene array analysis of 97 patients, increased 
expression was correlated with an intermediate or 
high risk for a poorer outcome, independent of 
patient age (Kang et al., 2012). Results were not 
confirmed at the protein level. 
Oncogenesis 
Upregulation of TACC2 may be triggered by the 
underlying alteration in the MLL gene in patients, 
resulting in recruitment of histone methylases to 
target genes.  
Proposed mechanism based on previous 
identification of the regulation of the TACC2 gene 




Identified as a marker of minimal residue disease 
based on Affymetrix U-95 gene chip expression 
array analysis of 48 stage 4 tumours and 9 
remission bone marrows.  
Expression of TACC2 in tumour as compared to 
marrow was superior to that of tyrosine 
hydroxylase, however, TACC2 expression failed to 
be of prognostic value for progression-free survival 
(Cheung et al., 2008). 
Intracranial ependymoma 
Prognosis 
Single allele deletion detected by high-resolution 
matrix-based CGH in 11/68 intracranial 
ependymoma (Mendrzyk et al., 2006), not linked to 
clinicopathologic subgroups. 
Oncogenesis 
Apparent overexpression from remaining allele in 




Decreased expression of TACC2 was noted in a 
survey of breast cancer samples by 
immunohistochemistry of tumour microarrays 
derived from 552 breast cancer patients 
(Jacquemier et al., 2005). In another study, 
"increased" levels of TACC2 were reported, based 
on quantitative rt-PCR and analysis of protein  
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levels in "macro-dissected" tumours, to be 
associated with poorer prognosis, grade and short 
disease-free survival (Cheng et al., 2010). However, 
the intensity of immunohistochemical staining of 
the tumour cells appeared to be the same as in 
normal breast epithelium used in the study. Thus, in 
this study, TACC2 staining may only reflect the 
percentage of the resected tumour tissue occupied 
by tumour cells and may reflect retention of 
expression of TACC2 at normal levels seen in the 
precursor mammary epithelial cells (Cheng et al., 
2010). 
Oncogenesis 
The TACC2 transcript AF176646 (AZU1) is 
downregulated in the more malignant derivatives of 
the HMT-3522 tumour progression cell model 
(Chen et al., 2000). Expression of exogenous 
TACC2 short isoforms (AF176646, AF095791 or 
AF528098) reduces malignant potential of breast 
tumour cells (Chen et al., 2000; Lauffart et al., 
2003). Tumor suppressor properties may operate 
through PLCγ (Cheng et al., 2011). 
Prostate cancer 
Prognosis 
Positive correlation between Gleason score and 
immunohistochemical staining for TACC2 noted in 
a survey of 103 prostate cancer samples (Takayama 
et al., 2012). 
Oncogenesis 
The TACC2 gene is androgen responsive, with two 
confirmed androgen receptor binding sites in intron 
4*; at 123870283-123870871 (Takayama et al., 
2012).  
TACC2 promotes cell proliferation in androgen 
sensitive and androgen-independent prostate cancer 
cells.  
A single-nucleotide polymorphism, rs3763763, 
inside an estrogen response element is associated 
with prostate cancer-specific mortality and "all-
cause mortality" after androgen-deprivation therapy 
(Huang et al., 2012) suggesting that hormonally 
regulated expression of TACC2 is important in the 
oncogenic process.  
It has been noted that TACC2 interacts with 
androgen receptor regulator FHL2 (Lauffart et al., 
2007b), a protein of known importance in 
attainment of androgen independence in prostate 
cancer (McGrath et al., 2013), suggesting potential 
positive feedback on TACC2 expression.  
*designated based on genomic structure of the 
AF528099 long form (see genomic model). 
Breakpoints 
Note 
No translocation or deletions within the TACC2 
gene have been identified. 
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